This Summer I started a collaboration with the University of Messina (Italy), on a totally different subject from my physics-related research: nuclear medicine and oncology! Here is the first paper in our series (open access):
Neuroendocrine tumours (NETs) constitute a diverse group of cancers characterized by heterogeneous biological hallmarks and variable behaviour, from slow-growing and indolent tumours to aggressive and rapidly fatal cancers. Somatostatin analogues (SSAs) provide the first line of their systemic treatment. In this paper we propose a scheduling optimization when SSAs are combined with peptide receptor radionuclide therapy (PRRT).